A Phase 2 Study of APX005M in Combination with Concurrent Chemo-radiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

Brief description of study

The purpose of the study is to determine the side effects of CD40 agonistic monoclonal antibody APX005M, chemotherapy, and radiation therapy, and to see how well they work when given before surgery in treating patients with esophageal cancer or gastroesophageal cancer that can be removed by surgery. APX005M is intended to stimulate the body's own immune system so that the immune cells can more effectively invade and destroy the tumor, adding to the benefits of the chemotherapy and radiation therapy. The study drug APX005M is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s20-01940
ClinicalTrials.gov Identifier: NCT03165994
Principal Investigator: Paul E. Oberstein.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.